Be careful Sunita as you're not so clean yourself funneling $ to friends, like BTL, to name a few.
-
Make it like cafepharma, but for different industries. Learn more about CompanyUnderground
Intarcia Therapeutics
- Thread starter anonymous
- Start date
-
- Tags
- None
Who is or was BTL? Bacon Tomato and Lettuce?
The Baron is firing off shots with both guns. She's big on everything in Medical straight up but KG wouldn't let me fix CMC. The Baron says sterility was covered up as long as possible until busted by FDA.
That's pile of BS. The baroness was part of KG's LT, headed and fully responsible for CMC, and willing partner in the fraud by signing the NDA. Guess she's got a target on her back too and ready to cooperate with the investigators and testify against KG and OH for lesser charges? Ah the irony... with sarc. 
Forbes offers encrypted emails - this can be used to safely submit info
Try this link https://www.forbes.com/tips/#4c688e41226a
Email
You may send us encrypted or unencrypted emails. Pretty Good Privacy (PGP) is an encryption protocol that allows you to send encrypted emails and attachments. If you use PGP encryption, here is our fingerprint and link to our public key. Please note: if you use our public key with a mail encryption plugin, for example Mailvelope or Enigmail, this encrypts the contents of your message but not the subject line or the name of the sender.
Fingerprint: 5C1E 52A8 7BBD A588 7074 C25C 7E44 EB55 2C36 951E + Public key
Email: tips@forbes.com
Try this link https://www.forbes.com/tips/#4c688e41226a
You may send us encrypted or unencrypted emails. Pretty Good Privacy (PGP) is an encryption protocol that allows you to send encrypted emails and attachments. If you use PGP encryption, here is our fingerprint and link to our public key. Please note: if you use our public key with a mail encryption plugin, for example Mailvelope or Enigmail, this encrypts the contents of your message but not the subject line or the name of the sender.
Fingerprint: 5C1E 52A8 7BBD A588 7074 C25C 7E44 EB55 2C36 951E + Public key
Email: tips@forbes.com
So inquiring minds wanna know. When was Intarcia informed by the 3rd party lab of the OOS for stability and sterility when Intracia confessed it to FDA in Jan 2018 resulting FDA demand a rare complete halt to the on-going trials?
How long did the management including CMC and QC/QA drag their feet concerning the root cause analysis which was reported to be inconclusive (or were there uncomfortable facts/data hidden and by whom)?
Whatever happened to the stability samples kept internally along with the test data down to the lab book and original source data? Was there disregard for the data integrity and what email communications were wiped clean? Will the peons speak the truth during the deposition?
Time to man/lawyer-up discoveries!
Time to rethink T2D as in disrupting Discovery, Deposition, Dissed, Disinformation to name a few, you dog!
75% of the workforce leaving at the end of this month. What's even crazier is who gets to stay (on the sinking ship) and probably got promoted earlier in the year.
Today was the last day for a lot of peeps at InSHITcia Hayweird. Good fxckin riddance.
When will the execs fail jail time?
When will the execs fail jail time?
Someone upload the PDF with the list of positions eliminated, you know theres one going around. Friends of friends are most of who is staying. Plus all the companies that were given contracts because they were friends with someone.
Is the Company still paying to rent recoding time for the asshats dogter
What !?! Reduction in farce ? Fired 75% of tha suckas ? Shit man MOFO rejected twice by FDA ROFLMAO
when ya stink up tha bowl ya gotta flush right away. These white dudes running a giant scam
when ya stink up tha bowl ya gotta flush right away. These white dudes running a giant scam
Keep those cellphones handy..
SEC Awards Record Payout of Nearly $50 Million to Whistleblower
Whistleblower Program Reaches $500 Million in Total Awards
FOR IMMEDIATE RELEASE
2020-126
Washington D.C., June 4, 2020 —
The Securities and Exchange Commission today announced a nearly $50 million whistleblower award to an individual who provided detailed, firsthand observations of misconduct by a company, which resulted in a successful enforcement action that returned a significant amount of money to harmed investors. This is the largest amount ever awarded to one individual under the SEC’s whistleblower program. The next largest is a $39 million award to an individual in 2018. Two individuals also shared a nearly $50 million whistleblower award that same year.
“This award marks several milestones for the whistleblower program,” said Jane Norberg, Chief of the SEC’s Office of the Whistleblower. “This award is the largest individual whistleblower award announced by the SEC since the inception of the program, and brings the total awarded to whistleblowers by the SEC to over $500 million, including over $100 million in this fiscal year alone. Whistleblowers have proven to be a critical tool in the enforcement arsenal to combat fraud and protect investors.”
SEC Awards Record Payout of Nearly $50 Million to Whistleblower
Whistleblower Program Reaches $500 Million in Total Awards
FOR IMMEDIATE RELEASE
2020-126
Washington D.C., June 4, 2020 —
The Securities and Exchange Commission today announced a nearly $50 million whistleblower award to an individual who provided detailed, firsthand observations of misconduct by a company, which resulted in a successful enforcement action that returned a significant amount of money to harmed investors. This is the largest amount ever awarded to one individual under the SEC’s whistleblower program. The next largest is a $39 million award to an individual in 2018. Two individuals also shared a nearly $50 million whistleblower award that same year.
“This award marks several milestones for the whistleblower program,” said Jane Norberg, Chief of the SEC’s Office of the Whistleblower. “This award is the largest individual whistleblower award announced by the SEC since the inception of the program, and brings the total awarded to whistleblowers by the SEC to over $500 million, including over $100 million in this fiscal year alone. Whistleblowers have proven to be a critical tool in the enforcement arsenal to combat fraud and protect investors.”
What Is Wire Fraud?
Wire fraud is a crime in which a person concocts a scheme to defraud or obtain money based on false representation or promises. This criminal act is achieved using analog or digital an interstate communications facility. These can include a phone call, a fax, an email, a text, or social media messaging, among many other forms. Wire fraud is punishable by prison and/or fines.
Wire fraud is a crime in which a person concocts a scheme to defraud or obtain money based on false representation or promises. This criminal act is achieved using analog or digital an interstate communications facility. These can include a phone call, a fax, an email, a text, or social media messaging, among many other forms. Wire fraud is punishable by prison and/or fines.
Just change Theranos to Intarcia, Lizzie Holmes to KG and Sunny Boy to OH:
U.S. v. Elizabeth Holmes, et al.
Elizabeth Holmes and Ramesh “Sunny” Balwani are charged with two counts of conspiracy to commit wire fraud and nine counts of wire fraud. According to the indictment, the charges stem from allegations that Holmes and Balwani engaged in a multi-million-dollar scheme to defraud investors, and a separate scheme to defraud doctors and patients. Both schemes involved efforts to promote Theranos, a company founded by Holmes and based in Palo Alto, California. Theranos was a private health care and life sciences company with the stated mission to revolutionize medical laboratory testing through allegedly innovative methods for drawing blood, testing blood, and interpreting the resulting patient data.
Holmes and Balwani used advertisements and solicitations to encourage and induce doctors and patients to use Theranos’s blood testing laboratory services, even though, according to the government, the defendants knew Theranos was not capable of consistently producing accurate and reliable results for certain blood tests. It is further alleged that the tests performed on Theranos technology were likely to contain inaccurate and unreliable results.
The indictment alleges that Holmes and Balwani defrauded doctors and patients (1) by making false claims concerning Theranos’s ability to provide accurate, fast, reliable, and cheap blood tests and test results, and (2) by omitting information concerning the limits of and problems with Theranos’s technologies. The defendants knew Theranos was not capable of consistently producing accurate and reliable results for certain blood tests, including the tests for calcium, chloride, potassium, bicarbonate, HIV, Hba1C, hCG, and sodium. The defendants nevertheless used interstate electronic wires to purchase advertisements intended to induce individuals to purchase Theranos blood tests at Walgreens stores in California and Arizona. Through these advertisements, the defendants explicitly represented to individuals that Theranos’s blood tests were cheaper than blood tests from conventional laboratories to induce individuals to purchase Theranos’s blood tests.
According to the indictment, the defendants also allegedly made numerous misrepresentations to potential investors about Theranos’s financial condition and its future prospects. For example, the defendants represented to investors that Theranos conducted its patients’ tests using Theranos-manufactured analyzers; when, in truth, Holmes and Balwani knew that Theranos purchased and used for patient testing third party, commercially-available analyzers. The defendants also represented to investors that Theranos would generate over $100 million in revenues and break even in 2014 and that Theranos expected to generate approximately $1 billion in revenues in 2015; when, in truth, the defendants knew Theranos would generate only negligible or modest revues in 2014 and 2015.
The indictment alleges that the defendants used a combination of direct communications, marketing materials, statements to the media, financial statements, models, and other information to defraud potential investors. Specifically, the defendants claimed that Theranos developed a revolutionary and proprietary analyzer that the defendants referred to by various names, including as the TSPU, Edison, or minilab. The defendants claimed the analyzer was able to perform a full range of clinical tests using small blood samples drawn from a finger stick. The defendants also represented that the analyzer could produce results that were more accurate and reliable than those yielded by conventional methods – all at a faster speed than previously possible. The indictment further alleges that Holmes and Balwani knew that many of their representations about the analyzer were false. For example, it is alleged that Holmes and Balwani knew that the analyzer had accuracy and reliability problems, performed a limited number of tests, was slower than some competing devices, and, in some respects, could not compete with existing, more conventional machines.
The indictment charges each defendant with two counts of conspiracy to commit wire fraud, in violation of 18 U.S.C. § 1349, and nine counts of wire fraud, in violation of 18 U.S.C. § 1343. If convicted, the defendants face a maximum sentence of twenty (20) years in prison, and a fine of $250,000, plus restitution, for each count of wire fraud and for each conspiracy count. However, any sentence following conviction would be imposed by the court after consideration of the U.S. Sentencing Guidelines and the federal statute governing the imposition of a sentence, 18 U.S.C. § 3553. Both defendants are currently out of custody.
U.S. v. Elizabeth Holmes, et al.
Elizabeth Holmes and Ramesh “Sunny” Balwani are charged with two counts of conspiracy to commit wire fraud and nine counts of wire fraud. According to the indictment, the charges stem from allegations that Holmes and Balwani engaged in a multi-million-dollar scheme to defraud investors, and a separate scheme to defraud doctors and patients. Both schemes involved efforts to promote Theranos, a company founded by Holmes and based in Palo Alto, California. Theranos was a private health care and life sciences company with the stated mission to revolutionize medical laboratory testing through allegedly innovative methods for drawing blood, testing blood, and interpreting the resulting patient data.
Holmes and Balwani used advertisements and solicitations to encourage and induce doctors and patients to use Theranos’s blood testing laboratory services, even though, according to the government, the defendants knew Theranos was not capable of consistently producing accurate and reliable results for certain blood tests. It is further alleged that the tests performed on Theranos technology were likely to contain inaccurate and unreliable results.
The indictment alleges that Holmes and Balwani defrauded doctors and patients (1) by making false claims concerning Theranos’s ability to provide accurate, fast, reliable, and cheap blood tests and test results, and (2) by omitting information concerning the limits of and problems with Theranos’s technologies. The defendants knew Theranos was not capable of consistently producing accurate and reliable results for certain blood tests, including the tests for calcium, chloride, potassium, bicarbonate, HIV, Hba1C, hCG, and sodium. The defendants nevertheless used interstate electronic wires to purchase advertisements intended to induce individuals to purchase Theranos blood tests at Walgreens stores in California and Arizona. Through these advertisements, the defendants explicitly represented to individuals that Theranos’s blood tests were cheaper than blood tests from conventional laboratories to induce individuals to purchase Theranos’s blood tests.
According to the indictment, the defendants also allegedly made numerous misrepresentations to potential investors about Theranos’s financial condition and its future prospects. For example, the defendants represented to investors that Theranos conducted its patients’ tests using Theranos-manufactured analyzers; when, in truth, Holmes and Balwani knew that Theranos purchased and used for patient testing third party, commercially-available analyzers. The defendants also represented to investors that Theranos would generate over $100 million in revenues and break even in 2014 and that Theranos expected to generate approximately $1 billion in revenues in 2015; when, in truth, the defendants knew Theranos would generate only negligible or modest revues in 2014 and 2015.
The indictment alleges that the defendants used a combination of direct communications, marketing materials, statements to the media, financial statements, models, and other information to defraud potential investors. Specifically, the defendants claimed that Theranos developed a revolutionary and proprietary analyzer that the defendants referred to by various names, including as the TSPU, Edison, or minilab. The defendants claimed the analyzer was able to perform a full range of clinical tests using small blood samples drawn from a finger stick. The defendants also represented that the analyzer could produce results that were more accurate and reliable than those yielded by conventional methods – all at a faster speed than previously possible. The indictment further alleges that Holmes and Balwani knew that many of their representations about the analyzer were false. For example, it is alleged that Holmes and Balwani knew that the analyzer had accuracy and reliability problems, performed a limited number of tests, was slower than some competing devices, and, in some respects, could not compete with existing, more conventional machines.
The indictment charges each defendant with two counts of conspiracy to commit wire fraud, in violation of 18 U.S.C. § 1349, and nine counts of wire fraud, in violation of 18 U.S.C. § 1343. If convicted, the defendants face a maximum sentence of twenty (20) years in prison, and a fine of $250,000, plus restitution, for each count of wire fraud and for each conspiracy count. However, any sentence following conviction would be imposed by the court after consideration of the U.S. Sentencing Guidelines and the federal statute governing the imposition of a sentence, 18 U.S.C. § 3553. Both defendants are currently out of custody.
Uh is promoting non-existent 1 year ITCA considered as wire fraud? How about no brainer FDA approval?
Dude how about the imaginary “synthetic royalty” on the Billions of dollars in sales ? Complete bullshit
We understand that the decision to come forward with information about securities fraud or other wrongdoing is not one taken lightly, and we are here to answer any questions you may have. You can reach the Office of the Whistleblower at (202) 551-4790.
SEC Office of the Whistleblower
NOTICE:
We strongly encourage the public (including whistleblowers) to submit any tips, complaints, and referrals (TCRs) using the SEC’s online TCR system and complaint form at https://www.sec.gov/tcr. If you submit your TCR using the online TCR system, you will receive a notice confirming that your submission has been received successfully and providing a submission number for your records.
Until further notice, any tips, complaints, and referrals submitted by mail (including whistleblower Form TCRs) should be sent to the following address due to the mandatory telework posture at the SEC’s Washington, DC headquarters: 14420 Albemarle Point Place, Suite 102, Chantilly, VA 20151-1750, ATTN: SEC TCR SUBMISSIONS
Submit a Tip
To qualify for an award under the Whistleblower Program, you must submit information regarding possible securities law violations to the Commission in one of the following two ways:
(1) By submitting a tip electronically through the SEC’s Tips, Complaints and Referrals Portal by clicking the button below.
(2) By mailing or faxing a Form TCR to:
14420 Albermarle Point Place
Suite 102
Chantilly, VA 20151-1750
ATTN: SEC TCR SUBMISSIONS
Fax: (703) 813-9322
You should maintain a copy of all documents and materials that you submit in connection with your whistleblower tip, including a mail receipt or fax confirmation. If you would like confirmation that your whistleblower tip was received by the Commission, you must enter your whistleblower tip through the online portal, where you have the option to print a confirmation receipt which provides the submission number and a copy of the tip.
If you are submitting additional information relating to a previously submitted tip, please reference your original TCR submission number.
If you are entering a whistleblower tip through the online portal and you wish to file jointly with another whistleblower, please note that the online system will only allow you to enter information for one whistleblower. If you wish to file online as joint whistleblowers, you should create a separate TCR for each whistleblower, and note in each TCR the name of the joint whistleblower.
NOTICE:
We strongly encourage the public (including whistleblowers) to submit any tips, complaints, and referrals (TCRs) using the SEC’s online TCR system and complaint form at https://www.sec.gov/tcr. If you submit your TCR using the online TCR system, you will receive a notice confirming that your submission has been received successfully and providing a submission number for your records.
Until further notice, any tips, complaints, and referrals submitted by mail (including whistleblower Form TCRs) should be sent to the following address due to the mandatory telework posture at the SEC’s Washington, DC headquarters: 14420 Albemarle Point Place, Suite 102, Chantilly, VA 20151-1750, ATTN: SEC TCR SUBMISSIONS
Submit a Tip
To qualify for an award under the Whistleblower Program, you must submit information regarding possible securities law violations to the Commission in one of the following two ways:
(1) By submitting a tip electronically through the SEC’s Tips, Complaints and Referrals Portal by clicking the button below.
(2) By mailing or faxing a Form TCR to:
14420 Albermarle Point Place
Suite 102
Chantilly, VA 20151-1750
ATTN: SEC TCR SUBMISSIONS
Fax: (703) 813-9322
You should maintain a copy of all documents and materials that you submit in connection with your whistleblower tip, including a mail receipt or fax confirmation. If you would like confirmation that your whistleblower tip was received by the Commission, you must enter your whistleblower tip through the online portal, where you have the option to print a confirmation receipt which provides the submission number and a copy of the tip.
If you are submitting additional information relating to a previously submitted tip, please reference your original TCR submission number.
If you are entering a whistleblower tip through the online portal and you wish to file jointly with another whistleblower, please note that the online system will only allow you to enter information for one whistleblower. If you wish to file online as joint whistleblowers, you should create a separate TCR for each whistleblower, and note in each TCR the name of the joint whistleblower.